Parallel Review Shouldn’t Entail Comparative Effectiveness, VCs Say

Any parallel product review process developed by FDA and CMS should not involve new requirements for comparative effectiveness data, the Medical Innovation and Competitiveness Coalition urges in recent comments to the agencies.